The optimized core peptide derived from CABIN1 efficiently inhibits calcineurin-mediated T-cell activation

Area of Science:

• Molecular Biology
• Immunology

Background:

• Calcineurin (a phosphatase) interacts with the nuclear factor of activated T cells (NFAT) to regulate T cell activity.
• The C-terminal fragment of CABIN1 (Calcium-binding protein 1) is known to interact with calcineurin and inhibit NFAT transcriptional activity.
• The precise binding mechanisms and sequences involved in the CABIN1-calcineurin interaction remain largely undefined.

Purpose of the Study:

• To elucidate the specific sequences and mechanisms by which the CABIN1 C-terminal fragment binds to calcineurin.
• To investigate the role of post-translational modifications, specifically phosphorylation, in modulating this interaction.
• To evaluate the potential of a defined CABIN1 peptide as a calcineurin inhibitor for therapeutic applications.

Main Methods:

• Peptide synthesis and binding assays to determine the minimal calcineurin-binding sequence of CABIN1.
• Site-directed mutagenesis to identify key residues and motifs involved in binding.
• In vitro kinase assays using p38MAPK to assess the effect of phosphorylation on binding affinity.
• Functional assays measuring T cell activation and calcineurin phosphatase activity.

Main Results:

• A decameric peptide (CABIN1 residues 2146-2155) was identified as the minimal sequence required for calcineurin binding.
• This peptide contains a critical "PxIxIT" N-terminal motif and a "PPTP" C-terminal sequence.
• Phosphorylation of the threonine residue within the "PPTP" motif by p38MAPK significantly enhanced the binding affinity to calcineurin.
• The modified CABIN1 peptide demonstrated superior inhibition of the calcineurin-NFAT pathway and T cell activation compared to the VIVIT peptide, without altering calcineurin's enzymatic activity.

Conclusions:

• The CABIN1 C-terminal peptide, particularly when phosphorylated, represents a potent inhibitor of the calcineurin-NFAT pathway.
• This enhanced binding and inhibitory capacity suggest significant therapeutic potential for conditions driven by aberrant calcineurin-NFAT signaling.
• The findings provide a mechanistic basis for developing novel therapeutics targeting T cell activation and related immune disorders.